The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom.
Michele A KohliMichael MaschioJoaquin F Mould-QuevedoMansoor AshrafMichael F DrummondMilton C WeinsteinPublished in: Vaccines (2021)
Vaccinating all 50- to 64-year-olds with QIVc is likely to be cost-effective. The NHS should consider continuing this policy in future seasons.